NCT07248280 Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
| NCT ID | NCT07248280 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Nausea and Vomiting, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2026-02-27 |
| Primary Completion | 2026-07-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Eligibility Criteria
Inclusion Criteria: * 18 years and over, requiring an ambulatory surgery * at high risk of post-operative nausea and vomitting defined by at least 3 factors from the Apfel score, calculated just prior to the surgery (female sex; non smoker; previous nausea or vomitting post-op., or motion sickness; expected opioid consumption in postoperative care). Exclusion Criteria: * Refusal or unable to consent * Suspected or documented allergy to aprepitant (emend) * Concomitant use of medication interacting via the cytochrome CYP3A4 with aprepitant (pimozide, terfenadine, astemizole, comtadin or cisapride).